Insider Selling: B Lynne Parshall Unloads 63,505 Shares of Isis Pharmaceuticals Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) COO B Lynne Parshall sold 63,505 shares of Isis Pharmaceuticals stock on the open market in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $31.04, for a total transaction of $1,971,195.20. Following the sale, the chief operating officer now directly owns 956 shares of the company’s stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on ISIS. Analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday. They now have a “hold” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Wednesday, September 4th. They set a “neutral” rating and a $26.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 20th. They now have a $27.00 price target on the stock.
Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $29.20.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded down 0.92% on Wednesday, hitting $31.33. 911,574 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 52-week low of $7.56 and a 52-week high of $34.31. The stock’s 50-day moving average is $27.52 and its 200-day moving average is $23.15. The company’s market cap is $3.613 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 19.5% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.